A retrospective study on the transition of radiation dose rate and iodine distribution in patients with I-131-treated well-differentiated thyroid cancer to improve bed control shorten isolation periods

[1] Tsuchimochi S(2001)Study on the isolation period of patients with metastatic thyroid cancer treated by Kaku Igaku (Jpn J Nucl Med) 38 747-754

[2] Nakajo M(2010)I according a new guideline Rad Fan 8 69-72

[3] Umanodan T(1998)Radionuclide therapy Jpn J Nucl Med Technol (published by Japanese society of Nuclear Medicine Technology) 18 72-78

[4] Fukushima N(1997)Evaluation of safety standards in patients treated with Jpn J Radiol Technol (published by Japanese Association of Radiological Technologists) 44 441-446

[5] Shigaki S(1992)I for metastasis from differentiated thyroid cancer J Nucl Med 33 1132-1136

[6] Kiku TA(1984)Days of hospital treatment and J Nucl Med 25 1287-1293

[7] Uchida Y(1983)I therapy for differentiated thyroid cancer patients—presumption under the measurement of 1 cm dose equivalent rate N Engl J Med 309 937-941

[8] Tanaka C(1999)Radioiodine-131 therapy for well-differentiated thyroid cancer—a quantitative radiation dosimetric approach: outcome and validation in 85 patients J Clin Endocrinol Metab 84 912-916

[9] Fujita T(2008)An analysis of “ablation of thyroid remnants” with I-131 in 511 patients from 1947 to 1984: experience at University of Michigan J Nucl Med 49 1445-1450

[10] Misaki T(2002)Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer J Nucl Med 43 61-65

[1] Tsuchimochi S(2001)Study on the isolation period of patients with metastatic thyroid cancer treated by Kaku Igaku (Jpn J Nucl Med) 38 747-754

[2] Nakajo M(2010)I according a new guideline Rad Fan 8 69-72

[3] Umanodan T(1998)Radionuclide therapy Jpn J Nucl Med Technol (published by Japanese society of Nuclear Medicine Technology) 18 72-78

[4] Fukushima N(1997)Evaluation of safety standards in patients treated with Jpn J Radiol Technol (published by Japanese Association of Radiological Technologists) 44 441-446

[5] Shigaki S(1992)I for metastasis from differentiated thyroid cancer J Nucl Med 33 1132-1136

[6] Kiku TA(1984)Days of hospital treatment and J Nucl Med 25 1287-1293

[7] Uchida Y(1983)I therapy for differentiated thyroid cancer patients—presumption under the measurement of 1 cm dose equivalent rate N Engl J Med 309 937-941

[8] Tanaka C(1999)Radioiodine-131 therapy for well-differentiated thyroid cancer—a quantitative radiation dosimetric approach: outcome and validation in 85 patients J Clin Endocrinol Metab 84 912-916

[9] Fujita T(2008)An analysis of “ablation of thyroid remnants” with I-131 in 511 patients from 1947 to 1984: experience at University of Michigan J Nucl Med 49 1445-1450

[10] Misaki T(2002)Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer J Nucl Med 43 61-65